FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC

(MedPage Today) -- Ahead of a meeting of the Oncologic Drugs Advisory Committee on Thursday, FDA reviewers raised a host of concerns about the confirmatory trial data for sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC...
Source: MedPage Today Public Health - Category: American Health Source Type: news